Logo

Trovagene Prices $20M Stock Offering

Feb 06, 2015 | staff reporter

NEW YORK (GenomeWeb) – Trovagene today priced a public offering of about 4.4 million shares of its common stock, anticipating gross proceeds of $20 million.

The company will use the proceeds to fund its R&D work and for working capital and other general corporate purposes. The offering is expected to close on or about Feb. 11. 

Piper Jaffray is the sole book-running manager, and Janney Montgomery Scott, Maxim Group, and Cantor Fitzgerald are the co-managers on the offering. Trovagene has granted the underwriters a 30-day option to purchase 666,666 shares of its common stock.

Trovagene reported it had $31.2 million in cash and cash equivalents as of Sept. 30, 2014. 

Shares of the San Diego-based molecular diagnostics firm were down 23 percent to $4.53 in Friday morning trading on the Nasdaq.

Filed under

Cancer
Business News
Biomarker Discovery & Validation
stock offering
Trovagene
Breaking News
The Scan

Machine Learning Helps ID Molecular Mechanisms of Pancreatic Islet Beta Cell Subtypes in Type 2 Diabetes

The approach helps overcome limitations of previous studies that had investigated the molecular mechanisms of pancreatic islet beta cells, the authors write in their Nature Genetics paper.

Culture-Based Methods, Shotgun Sequencing Reveal Transmission of Bifidobacterium Strains From Mothers to Infants

In a Nature Communications study, culture-based approaches along with shotgun sequencing give a better picture of the microbial strains transmitted from mothers to infants.

Microbial Communities Can Help Trees Adapt to Changing Climates

Tree seedlings that were inoculated with microbes from dry, warm, or cold sites could better survive drought, heat, and cold stress, according to a study in Science.

A Combination of Genetics and Environment Causes Cleft Lip

In a study published in Nature Communications, researchers investigate what combination of genetic and environmental factors come into play to cause cleft lip/palate.